STOCK TITAN

Viking Global discloses 3.7% NewAmsterdam Pharma (NAMS) holding in 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. received an updated Schedule 13G/A (Amendment No. 3) from investment entities affiliated with Viking Global, disclosing their passive ownership in the company’s ordinary shares.

The Viking-related entities collectively report beneficial ownership of 4,203,567 ordinary shares, representing 3.7% of the outstanding class, based on 113,390,804 ordinary shares outstanding as of October 31, 2025. The shares are held through two main limited partnerships, which directly own 2,817,205 and 1,386,362 ordinary shares, respectively. Key individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are reported as having shared voting and dispositive power over these holdings through their roles in Viking’s general partner and parent entities.

The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of NewAmsterdam Pharma, indicating a passive investment stance under the 13G framework.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Drawdown GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Drawdown Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Drawdown (Aggregator) LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
Date:02/17/2026
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:02/17/2026
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:02/17/2026
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:02/17/2026

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

What stake does Viking Global report in NewAmsterdam Pharma (NAMS)?

Viking-affiliated entities report beneficial ownership of 4,203,567 ordinary shares of NewAmsterdam Pharma, equal to 3.7% of the outstanding class. This percentage is based on 113,390,804 ordinary shares outstanding as of October 31, 2025, per the issuer’s Form 10-Q.

Which Viking entities are listed as reporting persons for NAMS?

Reporting persons include Viking Global Investors LP, multiple Viking Global Opportunities entities (Parent, GP, Portfolio GP, Illiquid Investments Sub-Master, Drawdown GP, Drawdown Portfolio GP, Drawdown Aggregator), and individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, all acting together as a reporting group.

How are Viking’s NewAmsterdam Pharma (NAMS) shares held and controlled?

The filing shows 2,817,205 shares directly owned by VGOP and 1,386,362 shares directly owned by VGOD. Various Viking general partner and parent entities, along with key executives, have shared voting and dispositive power over these positions under Rule 13d-3’s beneficial ownership framework.

Is Viking Global’s position in NAMS a passive investment?

Yes. The certification states the securities were not acquired and are not held to change or influence control of NewAmsterdam Pharma. Instead, they are reported on Schedule 13G/A, which is typically used for investors taking a passive ownership approach under SEC rules.

Why does each Viking entity show different ownership percentages in NAMS?

Percentages reflect each entity’s deemed beneficial ownership under Rule 13d-3. For example, VGI and Opportunities Parent each report 3.7%, while certain subsidiary entities report 2.5% or 1.2%, depending on whether they are linked only to VGOP, only to VGOD, or to both partnerships.

What share count did Viking use to calculate its NAMS ownership percentage?

The percentages are based on 113,390,804 ordinary shares outstanding as of October 31, 2025. This figure comes from NewAmsterdam Pharma’s quarterly report on Form 10-Q filed with the SEC on November 5, 2025, as referenced in the ownership section.
NewAmsterdam Pharma Company N.V

NASDAQ:NAMS

NAMS Rankings

NAMS Latest News

NAMS Latest SEC Filings

NAMS Stock Data

3.93B
96.06M
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
NARRDEN